- Previous Close
21.01 - Open
20.61 - Bid 21.44 x --
- Ask 21.45 x --
- Day's Range
20.64 - 21.50 - 52 Week Range
19.46 - 30.64 - Volume
9,210,608 - Avg. Volume
9,170,042 - Market Cap (intraday)
15.674B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
18.97 - EPS (TTM)
1.13 - Earnings Date --
- Forward Dividend & Yield 0.35 (1.67%)
- Ex-Dividend Date Dec 17, 2024
- 1y Target Est
32.50
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is based in Taiyuan, China.
www.slbiop.comRecent News: 000403.SZ
View MorePerformance Overview: 000403.SZ
Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000403.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000403.SZ
View MoreValuation Measures
Market Cap
15.36B
Enterprise Value
14.20B
Trailing P/E
18.51
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.39
Price/Book (mrq)
1.96
Enterprise Value/Revenue
4.99
Enterprise Value/EBITDA
14.99
Financial Highlights
Profitability and Income Statement
Profit Margin
29.14%
Return on Assets (ttm)
6.53%
Return on Equity (ttm)
11.08%
Revenue (ttm)
2.84B
Net Income Avi to Common (ttm)
828.65M
Diluted EPS (ttm)
1.13
Balance Sheet and Cash Flow
Total Cash (mrq)
1.75B
Total Debt/Equity (mrq)
7.62%
Levered Free Cash Flow (ttm)
185.23M